“Top leadership” from all commodity centers within the US Food and Drug Administration will take part in a new Inspectional Affairs Council that’s being stood up by the agency’s Office of Regulatory Affairs (ORA).
The council will be “focused on optimizing inspections as part of the agency’s regulatory oversight,” said Judith McMeekin, associate commissioner...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?